Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.25    2.75 (6.47%)
Bid:
44.50
Ask:
46.00
Spread: 1.50 (3.371%)
Market Cap: £86.82m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

H1 2021 Update

15 Jul 2021 07:00

RNS Number : 2760F
Iofina PLC
15 July 2021
 

 

 

 

Iofina Plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

H1 2021 Update

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update to the market regarding its activities during the first half of 2021 ("H1" or the "Period").

 

Highlights

 

· Strong sales period with demand for Iofina iodine and halogen derivative products increasing as customer markets reopen

· Spot iodine prices have moved slightly higher to $35-37/kg, providing further increases in revenue

· H1 production of 249.4MT of crystalline iodine, in line with revised forecast of 250MT

· Expansion plans progressing well and IO#9 construction expected to begin by year end

 

The iodine market has continued its recovery, with prices now $35-37/kg, and the Company is seeing good demand for its iodine and halogen derivative products. Importantly, Iofina has been able to meet this demand and deliver strong H1 2021 sales, despite the interruption to the brine water supply at some plants in February. During H1 2021, 249.4 metric tonnes ("MT") of crystalline iodine was produced from Iofina's five operating IOsorb® plants, which was in line with the forecast cited in Company's Q1 2021 update.

 

For H2 2021, the Company is anticipating iodine production of 260-275MT, with operational changes at a brine partner's sites affecting supply levels to two of our plants this year. Despite this, Iofina believes it is currently on track to achieve full year revenue and profit targets.

 

The Company is working to increase brine supply and, given the recovery in the oil market, is anticipating some reinvestment in oil fields by its partners, which would boost brine output. The Company is also progressing well with expansion plans for IO#9 to further offset any reduced supply, with construction expected to commence by the end of the year.

 

 

Commenting, President and CEO of Iofina Dr. Tom Becker, stated: "The iodine market is seeing an excellent recovery in line with the rapidly accelerating global economic recovery as we begin to emerge from the challenging COVID-19 period. Demand is strong and prices are back at pre-pandemic levels of around $35-$37/kg, supporting higher revenue expectations. We are also seeing excellent recovery in the oil markets with prices up to around $75/bbl, which we are hopeful will result in increased reinvestment by our partners into their oil fields.

 

"I am also pleased with the progress being made towards IO#9 and we are expecting to begin construction of this new plant by the end of the year. This will not only reduce any risk from reduced brine supply seen by any of our plants but also ensure we are well positioned to meet the rising demand we are seeing globally for iodine and its derivative products.

 

"In spite of lower production, we are fulfilling demand with our capacity and we remain on track to meet full year expectations. The Company continues to meet its debt obligations and is in an excellent position to continue with our prudent growth strategy. I look forward to updating the market further on our expansion as well as provide a fuller update on the Period at our interim results."

 

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Tim Harper (Corporate Finance)

Tim Redfern (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Joe Burgess

Yellow Jersey PR Limited

Tel: +44 (0)20 3004 9512

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of Iodine and the manufacturing of specialty chemical products. As the second largest producer of iodine in North America, it comprises three USA entities; Iofina Resources, Iofina Chemical and IofinaEX.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products for over 35 years.

 

www.iofina.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFEEDDISLIL
Date   Source Headline
5th Apr 20128:05 amRNSPurchase of Production Site & Recycling Initiative
2nd Apr 20125:01 pmRNSHolding(s) in Company
29th Mar 201212:11 pmRNSHolding(s) in Company
19th Mar 20127:00 amRNSCorporate Update
25th Nov 20117:00 amRNSDirector/PDMR Shareholding
24th Nov 20117:00 amRNSDirector/PDMR Shareholding
17th Oct 20117:00 amRNSHolding(s) in Company
27th Sep 20117:00 amRNSHalf Yearly Report
9th Aug 20117:00 amRNSTrading Update
30th Jun 20114:42 pmRNSResult of AGM
24th Jun 201111:42 amRNSHolding(s) in Company
8th Jun 20117:00 amRNSAmbrian Partners Appointed Joint Broker to Iofina
7th Jun 20117:00 amRNSIofina Reports Audited Full Year Financials
31st May 20116:03 pmRNSHolding(s) in Company
4th May 20114:32 pmRNSHolding(s) in Company
4th May 20114:29 pmRNSHolding(s) in Company
28th Apr 201112:58 pmRNSHolding(s) in Company
20th Apr 20117:00 amRNSPlacing
13th Apr 20116:28 pmRNSHolding(s) in Company
25th Mar 20117:00 amRNSContract Win
18th Mar 20117:00 amRNSHolding(s) in Company
1st Mar 20113:35 pmRNSHolding(s) in Company
27th Jan 20115:27 pmRNSHolding(s) in Company
12th Jan 20114:40 pmRNSSecond Price Monitoring Extn
12th Jan 20114:35 pmRNSPrice Monitoring Extension
3rd Dec 201012:46 pmRNSOperations Update
19th Oct 20105:30 pmRNSHolding(s) in Company
29th Sep 20109:26 amRNSHolding(s) in Company
28th Sep 20107:01 amRNSInterim Results
28th Sep 20107:00 amRNSAppointment of Finance Director
31st Aug 20107:00 amRNSFourth Extraction and Collection Agreement Signed
16th Jul 20105:57 pmRNSHolding in Company - Replacement
16th Jul 20105:02 pmRNSHoldings in Company
7th Jul 201010:00 amRNSResult of AGM
4th Jun 20107:00 amRNSFinal Results
20th May 20107:00 amRNSNew Agreement Signed and Operations Update
4th May 20107:00 amRNSIssuance of Permit
14th Apr 20107:00 amRNSThird Party Iodine Agreement Signed
22nd Mar 20108:36 amRNSFirst Third Party Iodine Extraction and Collection
22nd Mar 20107:00 amRNSRe Iodine Extraction and Collection Agreement
8th Mar 20107:02 amRNSOperations Update
8th Mar 20107:00 amRNSManagement changes
12th Jan 20103:09 pmRNSDirectorate Change
8th Jan 20107:00 amRNSDirector's Dealings
11th Dec 20096:00 pmRNSHolding in Company
22nd Oct 20095:14 pmRNSChange of Name of Nominated Adviser
19th Oct 20094:07 pmRNSExercise of Options
30th Sep 20097:00 amRNSHalf Yearly Report
10th Aug 200911:13 amRNSManagement Appointments
27th Jul 20097:00 amRNSAcquisition and Operations Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.